I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell of lymphatic vessel | 6 studies | 27% ± 7% | |
| epithelial cell | 3 studies | 19% ± 1% | |
| macrophage | 3 studies | 21% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell of lymphatic vessel | 6 studies | 27% ± 7% | |
| epithelial cell | 3 studies | 19% ± 1% | |
| macrophage | 3 studies | 21% ± 3% |
Insufficient scRNA-seq data for expression of TNFRSF11A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| intestine | 92% | 1446.90 | 890 / 966 | 97% | 14.34 | 513 / 527 |
| pancreas | 93% | 243.78 | 305 / 328 | 93% | 9.52 | 165 / 178 |
| prostate | 97% | 347.27 | 237 / 245 | 87% | 2.74 | 439 / 502 |
| stomach | 88% | 272.75 | 316 / 359 | 95% | 14.29 | 273 / 286 |
| lung | 94% | 280.97 | 544 / 578 | 86% | 4.78 | 992 / 1155 |
| breast | 93% | 552.41 | 427 / 459 | 87% | 3.67 | 970 / 1118 |
| esophagus | 88% | 318.16 | 1275 / 1445 | 89% | 10.38 | 162 / 183 |
| thymus | 99% | 418.11 | 644 / 653 | 64% | 1.52 | 387 / 605 |
| uterus | 91% | 169.29 | 154 / 170 | 70% | 2.77 | 323 / 459 |
| bladder | 90% | 332.14 | 19 / 21 | 69% | 4.89 | 348 / 504 |
| skin | 78% | 445.79 | 1420 / 1809 | 49% | 1.37 | 229 / 472 |
| brain | 58% | 157.81 | 1520 / 2642 | 62% | 1.49 | 437 / 705 |
| ovary | 43% | 81.19 | 78 / 180 | 56% | 1.33 | 241 / 430 |
| adrenal gland | 86% | 267.09 | 222 / 258 | 13% | 0.41 | 29 / 230 |
| adipose | 98% | 440.11 | 1176 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 3.74 | 40 / 45 |
| kidney | 42% | 80.74 | 37 / 89 | 43% | 1.08 | 390 / 901 |
| spleen | 83% | 177.91 | 201 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 63% | 181.03 | 835 / 1335 | 0% | 0 | 0 / 0 |
| liver | 25% | 32.46 | 56 / 226 | 37% | 1.48 | 149 / 406 |
| heart | 52% | 90.33 | 451 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 38% | 216.46 | 352 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 11% | 0.15 | 9 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.15 | 3 / 29 |
| muscle | 7% | 7.70 | 53 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0043507 | Biological process | positive regulation of JUN kinase activity |
| GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
| GO_0030316 | Biological process | osteoclast differentiation |
| GO_0048535 | Biological process | lymph node development |
| GO_0007165 | Biological process | signal transduction |
| GO_0032868 | Biological process | response to insulin |
| GO_0014070 | Biological process | response to organic cyclic compound |
| GO_0060749 | Biological process | mammary gland alveolus development |
| GO_0070555 | Biological process | response to interleukin-1 |
| GO_0034612 | Biological process | response to tumor necrosis factor |
| GO_0045471 | Biological process | response to ethanol |
| GO_0007267 | Biological process | cell-cell signaling |
| GO_0045672 | Biological process | positive regulation of osteoclast differentiation |
| GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0072674 | Biological process | multinuclear osteoclast differentiation |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0060086 | Biological process | circadian temperature homeostasis |
| GO_0071812 | Biological process | positive regulation of fever generation by positive regulation of prostaglandin secretion |
| GO_0009612 | Biological process | response to mechanical stimulus |
| GO_0001503 | Biological process | ossification |
| GO_0002548 | Biological process | monocyte chemotaxis |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0045780 | Biological process | positive regulation of bone resorption |
| GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
| GO_0032496 | Biological process | response to lipopolysaccharide |
| GO_0034224 | Biological process | cellular response to zinc ion starvation |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0045121 | Cellular component | membrane raft |
| GO_0005829 | Cellular component | cytosol |
| GO_0038023 | Molecular function | signaling receptor activity |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0019955 | Molecular function | cytokine binding |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0005031 | Molecular function | tumor necrosis factor receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TNFRSF11A |
| Protein name | Tumor necrosis factor receptor superfamily member 11A (Osteoclast differentiation factor receptor) (ODFR) (Receptor activator of NF-KB) (CD antigen CD265) |
| Synonyms | RANK |
| Description | FUNCTION: Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis . Its interaction with EEIG1 promotes osteoclastogenesis via facilitating the transcription of NFATC1 and activation of PLCG2 (By similarity). Involved in the regulation of interactions between T-cells and dendritic cells (By similarity). . |
| Accessions | ENST00000586569.3 [Q9Y6Q6-1] ENST00000269485.11 [Q9Y6Q6-2] Q9Y6Q6 |
